Related Experiment Video
Updated: Aug 15, 2026
One-day Workflow Scheme for Bacterial Pathogen Detection and Antimicrobial Resistance Testing from Blood Cultures
Published on: July 9, 2012
Comparative in vitro activity of cefpirome (HR 810) against gram-positive isolates from cancer patients
Abstract:
The activity of cefpirome against gram-positive isolates from cancer patients was compared to that of currently available extended-spectrum cephalosporins. Cefpirome was active against methicillin-susceptible, coagulase-positive, and coagulase-negative staphylococci. It was the most active agent against streptococci belonging to Lancefield groups A, B and G and Streptococcus pneumoniae. 76% of enterococcal isolates were susceptible to cefpirome - far more than any of the other agents tested.
Insights
Cefpirome shows strong activity against Gram-positive bacteria, including staphylococci and streptococci, in cancer patients. It demonstrated superior efficacy against enterococci compared to other tested cephalosporins.
Area of Science:
- Clinical microbiology
- Infectious diseases
- Pharmacology
Background:
- Cancer patients are susceptible to Gram-positive bacterial infections.
- Extended-spectrum cephalosporins are crucial for treating these infections.
- Understanding antibiotic activity against resistant strains is vital.
Purpose of the Study:
- To evaluate the in vitro activity of cefpirome against Gram-positive isolates from cancer patients.
- To compare cefpirome's efficacy with existing extended-spectrum cephalosporins.
- To identify optimal antibiotic choices for Gram-positive infections in immunocompromised individuals.
Main Methods:
- In vitro susceptibility testing of cefpirome and other extended-spectrum cephalosporins.
- Testing was performed on Gram-positive bacterial isolates obtained from cancer patients.
- Standard microbiological methods were employed to determine minimum inhibitory concentrations.
Main Results:
- Cefpirome exhibited significant activity against methicillin-susceptible staphylococci (coagulase-positive and negative).
- It was the most potent agent against Lancefield groups A, B, G streptococci and Streptococcus pneumoniae.
- A high susceptibility rate (76%) to cefpirome was observed in enterococcal isolates, exceeding other tested agents.
Conclusions:
- Cefpirome demonstrates broad-spectrum activity against key Gram-positive pathogens in cancer patients.
- Its potent activity against streptococci and high efficacy against enterococci suggest a valuable role in treating infections in this vulnerable population.
- Cefpirome represents a promising therapeutic option for Gram-positive bacterial infections in immunocompromised hosts.
